Cancer treatment: First Phase III trial of an alpha-pharmaceutical shows promising results

The first Phase III study of an alpha-pharmaceutical (Radium-223 Chloride -- Alpharadin) in patients with bone metastases from advanced prostate cancer has shown that it can prolong survival significantly. Until now, options for these patients have been very limited. The ALSYMPCA trial had to be stopped early after interim analysis revealed that patients receiving the best standard treatment plus radium-223 were living longer than those who were receiving the same standard treatment plus placebo.

Read the whole article on Science Daily

More from Science Daily